Jamalinia Mohamad, Mirhosseini Seyed Alireza, Ranjbar Maryam, Bagheri Lankarani Kamran, Hosseinzadeh Ahmad
Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Cardiovascular Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Sci Rep. 2025 Jan 26;15(1):3301. doi: 10.1038/s41598-025-88133-x.
Abdominal Aortic Aneurysm (AAA) poses a significant health risk due to its silent nature and high mortality upon rupture. The Fib-4 index, initially designed for liver fibrosis assessment, presents potential beyond its scope. This study aims to investigate the association of FIB-4 with aneurysm size and mortality risk, exploring its utility as a risk predictor for enhanced clinical management. This retrospective longitudinal research studied 141 AAA open repair surgery patients (92% male, mean age of 70 years (SD: 11.5)) from October 2016 to September 2021 for a median follow-up 35 months (IQR: 0.7 - 56.6). All-cause mortality was the primary outcome. Adjusted hazard ratios (aHR) were calculated for each Fib-4 cut-off between 1.5 and 3.25. FIB-4 cut-off range of 2.58-2.74 was associated with higher mortality risk in adjusted HR. Specifically, FIB-4 ≥ 2.67 increased mortality by 78% (aHR:1.78, 95% CI: 1.06 - 3.00). Furthermore, FIB-4 ≥ 2.67 was significantly associated with a baseline aneurysm size ≥ 8cm (aOR: 2.67, 95% CI: 1.17 - 6.09). FIB-4 was independently associated with a higher mortality risk and higher aneurysm size. These findings suggest that FIB-4 assessment in clinical practice may enhance risk profiling, aiding in more precise stratification and management strategies for AAA patients.
腹主动脉瘤(AAA)因其隐匿性和破裂时的高死亡率而构成重大健康风险。Fib-4指数最初用于评估肝纤维化,但其应用潜力超出了这一范围。本研究旨在探讨Fib-4与动脉瘤大小及死亡风险之间的关联,探索其作为风险预测指标在改善临床管理方面的效用。这项回顾性纵向研究对2016年10月至2021年9月期间接受AAA开放修复手术的141例患者(92%为男性,平均年龄70岁(标准差:11.5))进行了研究,中位随访时间为35个月(四分位间距:0.7 - 56.6)。全因死亡率是主要结局。计算了1.5至3.25之间每个Fib-4临界值的调整后风险比(aHR)。在调整后的HR中,Fib-4临界值范围为2.58 - 2.74与较高的死亡风险相关。具体而言,FIB-4≥2.67使死亡率增加78%(aHR:1.78,95%置信区间:1.06 - 3.00)。此外,FIB-4≥2.67与基线动脉瘤大小≥8cm显著相关(aOR:2.67,95%置信区间:1.17 - 6.09)。Fib-4与较高的死亡风险和较大的动脉瘤大小独立相关。这些发现表明,在临床实践中进行Fib-4评估可能会改善风险评估,有助于对AAA患者进行更精确的分层和管理策略。